FindTrial
Sign In

Single Centre Experience of Her2 Neu utility In Carcinoma Gall Bladder

Single Centre Experience of Her2 Neu Frequency And Therapeutic Implications In Carcinoma Gall Bladder - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/059313
Enrollment
51
Registered
2023-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C23- Malignant neoplasm of gallbladder

Interventions

Intervention1: Nil: Nil

Sponsors

Institute of Medical Sciences and SUM Hospital SOA University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients with a confirmed diagnosis of Carcinoma gallbladder will be included in the study 2. ECOG PS 0-2

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years 2. Consent refusal for treatment 3. Patients with histological type: Neuroendocrine

Design outcomes

Primary

MeasureTime frame
To evaluate the overall survival in Her2 neu overexpressed Ca GB patients. Timepoint: 3 months—

Secondary

MeasureTime frame
1. To determine the Progression-free survival (PFS-2) in Her2 neu overexpressed Ca GB patients on 2nd line chemotherapy in combination with targeted therapy. 2. To determine the Prevalence of Her2 neu overexpression in Ca GB patients. Timepoint: 2 months—

Countries

India

Contacts

Public ContactDr Soumya Surath Panda

Institute of Medical sciences and SUM Hospital

soumyasurathpanda@soa.ac.in8895370579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026